Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And CompanyfiledCriticalEli Lilly And Company
Priority to YU34793ApriorityCriticalpatent/YU34793A/sh
Publication of YU34793ApublicationCriticalpatent/YU34793A/sh
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Derivat ljudskog proteina C odabran iz grupe koja se sastoji od Q3Q9, FLIN-Q313 i FLIN-Q3Q9; rekom-binantni molekul DNK odabran iz grupe koja se sastoji od plazmida pGT-h-Q3Q9 (NRRL B-18938), plazmida pGT-h-FLIN-Q313 (NRRL B-18939) i plazmida pGT-h-FLIN-Q3Q9 (NRRL B-18940); ćelija domaćin koja predstavlja 293/pGT-h-Q3Q9, 293/pGT-h-FLIN-Q3Q13, 293/pGT-h-FLIN-Q3Q9, E. coli K12 AG1/pGTQ3Q9 (NRRL B-18938), E. coli K12 AG1/pGT-h-FLIN-Q313 (NRRL B-18939) i E. coli K12 AG1/pGT-h-FLIN-Q3Q9 (NRRL B-18940); i farmaceutska formulacija koja obuhvata kao aktivnu komponentu derivat proteina C odabran iz grupe koja se sastoji do Q3Q9, FLIN-Q313 i FLIN-Q3Q9, zajedno sa jednim ili više farmaceutski prihvatljivih nosača, ekscipijenata ili razblaživača.
YU34793A1993-05-191993-05-19Derivati proteina c
YU34793A
(sh)